Chief Development Officer
Matinas BioPharma Holdings, Inc.
Bedminster NJ, NJ, United States
Dr. Theresa Matkovits has more than 20 years of experience as a leader in global drug development and commercialization, with extensive expertise across a number of therapeutic areas including psychiatry, women’s health, cardiovascular, and infectious diseases. She currently serves as the Chief Development Officer at Matinas Biopharma where she serves as an Executive Leadership Team member, joining the company in October 2018. Dr. Matkovits is responsible for leading the Global Development efforts for the company’s clinical-stage pipeline products. Prior to this role, Dr. Matkovits was the Chief Operating Officer at ContraVir (Nasdaq: CTRV) now Hepion, where she led global development of the company’s clinical-stage antiviral portfolio. Dr. Matkovits’ career also includes steering the clinical development and approval efforts for Natpara® at NPS Pharmaceuticals; serving as a Vice President and Innovation Leader at The Medicines Company (Nasdaq: MDCO), where she managed global development and commercialization efforts for the Company’s infectious disease franchise; and several global leadership positions at Novartis in its U.S. Medical and Drug Regulatory Affairs and Global Development Divisions where she was instrumental in leading the development of the company’s psychiatry portfolio of products. Dr. Matkovits is currently a member of the Board of Directors for Appili Therapeutics where she is a member of the Audit Committee and Chair of the Nominating and Compensation Committee. Dr. Matkovits earned her Ph.D. in Biochemistry and Molecular Biology from the University of Medicine and Dentistry of New Jersey - New Jersey Medical School.
Disclosure(s): Matinas BioPharma Holdings, Inc.: Employee (Ongoing)
Thursday, October 12, 2023
8:12 AM – 8:24 AM US ET